Dengue and West Nile viruses (WNV) are mosquito-borne members of flaviviruses that cause significant morbidity and mortality. There is no approved vaccine or antiviral drugs for human use to date. In this study, a series of functionalized meta and para aminobenzamide derivatives were synthesized and subsequently screened in vitro against Dengue virus and West Nile virus proteases. Four active compounds were identified which showed comparable activity toward the two proteases and shared in common a meta or para(phenoxy)phenyl group. The inhibition constants (K i ) for the most potent compound 7n against Dengue and West Nile virus proteases were 8.77 and 5.55 µM, respectively. The kinetics data support a competitive mode of inhibition of both proteases by compound 7n. This conclusion is further supported by molecular modeling. This study reveals a new chemical scaffold which is amenable to further optimization to yield potent inhibitors of the viral proteases via the combined utilization of iterative medicinal chemistry/structure-activity relationship studies and in vitro screening.
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Introduction
The Dengue virus (DENV) and West Nile Virus (WNV) are members of the family Flaviviridae which comprise several human and animal pathogens, including
Yellow fever virus (YFV), Hepatitis C virus (HCV), and Japanese encephalitis virus (JEV). 1 Infection by DENV1-4 serotypes results in Dengue fever which can progress to life-threatening Dengue hemorrhagic fever (DHF) and Dengue shock syndrome (DSS). 2 Dengue infection is a global health threat for which there are currently no small molecule antiviral therapeutics or effective vaccines. Inhibition of DENV replication constitutes a promising avenue of investigation for the development of therapeutics against DENV. [3] [4] [5] Both Dengue and West Nile viruses are small, enveloped viruses containing a positive-stranded 11-kb RNA genome which encodes a polyprotein precursor which is co-and post-translationally processed by host cell proteases and the viral encoded trypsin-like protease, NS2B/NS3, into three structural proteins (C, prM, E) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5). [6] [7] NS3 is a multi-functional protein containing a serine protease with a prototypical catalytic triad (H51, D75, S135) within the N-terminal 185 amino acid residues, an NTPase/RNA helicase, and a 5'-RNA triphosphatase within the C-terminal (161-618 amino acid residues) region of NS3. 4, [5] [6] Activation of the serine protease domain of NS3 requires NS2B cofactor, a ~130 amino acid hydrophobic integral membrane protein in the endoplasmic reticulum (ER). A ~45 amino acid conserved hydrophilic segment from the NS2B sequence is sufficient for interaction with and activation of the NS3 protease domain for protease activity (hereafter referred to as "NS2B/NS3pro") in vitro. 5, [7] [8] Processing of the polyprotein by NS2B/NS3pro is essential for viral replication, consequently NS2B/NS3pro has emerged as an attractive target for the discovery and development of small molecule therapeutics for DENV infection. [3] [4] [5] [6] DENV NS2B/NS3pro has a substrate specificity for an -X-K-R-R-G/Ssequence corresponding to the subsites -S 4 -S 3 -S 2 -S 1 -S 1 '-. 9 Cleavage is at the P 1 -P 1 ' (R-G/S) scissile bond. The hydrophilic β-hairpin segment of the NS2B protein cofactor wraps around the NS3 protease core and is required for optimal catalytic efficiency. 10-12 Crystallographic 12-13 and high-field NMR studies 14 have illuminated greatly our understanding of the role played by the NS2B cofactor and the nature of the interaction of NS2B/NS3pro with small-molecule inhibitors.
DENV NS2B/NS3pro plays a vital role in virus replication, consequently, orallybioavailable drug-like agents that inhibit NS2B/NS3pro are of value as potential therapeutics for DENV infection. Inhibitors of NS2B/NS3pro containing a highly charged peptidyl recognition element with a dibasic motif at P 1 -P 2 coupled to an array of electrophilic warheads (aldehydes, trifluoromethyl ketones, and boronic acids), [15] [16] [17] [18] non-peptidyl α-ketoamides, 19 phthalazine-based derivatives, 20 arylcyanoacrylamides, 21 retro peptide-hybrids,
derivatives, 23 and others [24] [25] have been reported. We describe herein the results of synthetic and biochemical studies related to the inhibition of DENV and WNV NS2B/NS3pro by functionalized para-and meta-substituted aminobenzamide derivatives represented by structure (I) (Figure 1 ).
[ Figure 1 ]
Chemistry
Compounds 7a-t (Table 1) and 8a-f (Table 2) [ Table 2] corresponding isocyanate which was reacted with propargylamine to form urea derivatives 2a-b. Click chemistry 26 with an array of structurally diverse azides yielded the corresponding functionalized urea derivatives which were further elaborated to form the final compounds.
Biochemistry
The expression and purification of DENV NS2B/NS3pro and WNV NS2B/NS3pro have been previously described. [27] [28] [29] Enzyme assays and inhibition studies were carried out as previously described [30] [31] [32] and the results are summarized in [ [ Table 3] [ Table 4 ]
Results and Discussion
The world-wide health problem stemming from infection by Dengue virus and related flaviviruses, as well as the paucity of small-molecule therapeutics for combating flavivirus infection, have provided the impetus for the research described herein. The aminobenzamide scaffold was utilized in the synthesis of a series of structurally-diverse meta and para-substituted derivatives, represented by general structure (I), (Figure 1 ). The design of (I) rested on the following considerations: (a) the shallow active site of DENV NS2B/NS3pro presents a formidable challenge in terms of the design of potent inhibitors of the enzyme, necessitating the use of a suitably-embellished multifunctional molecule capable of engaging in multiple favorable binding interactions with the enzyme in order to attain high potency, without compromising oral bioavailability and PK characteristics. [33] [34] [35] [36] [37] [38] [39] [40] The problem is further compounded by the stringent substrate specificity requirements of the protease for positively charged substrates/inhibitors; (b) based on insights gained from examining the X-ray crystal structures of DENV2 NS2B/NS3pro with bound ligands [12] [13] and molecular modeling studies, it was hypothesized that the utilization of a planar platform capable of orienting appended non-peptidyl recognition elements in a preciselydefined vector relationship would lead to agents capable of interacting with multiple active site residues. Thus, the aminobenzamide platform was chosen for generating the desired compounds and for conducting exploratory studies. An added advantage is the flexibility afforded by the two points of diversity in the chosen scaffold, augmenting synthetic tractability; (c) a urea functionality was initially employed to lessen the conformational flexibility of the appended recognition elements. The latter included an electron-rich heterocycle having multiple hydrogen bond acceptor sites linked to an aryl alkyl group and, (d) it was furthermore envisaged that the initial attachment of an array of structurallydiverse aliphatic and aromatic amines to the carboxyl group of the aminobenzamide scaffold would provide additional binding sites.
The desired compounds were readily obtained as shown in Scheme 1. These were subsequently screened against DENV NS2B/NS3pro and WNV NS2B/NS3pro. Four of the compounds based on (I) were found to exhibit activity against both proteases and the results are summarized in Table 3 and Figure 2 .
It can be generally inferred from the SAR studies that the nature of both R 1 and R 2 influence activity. Furthermore, activity is manifested when R 1 is a meta or p-(phenoxy)phenyl group. All other amides were inactive, suggesting that the meta or p-(phenoxy)phenyl group is accommodated in a hydrophobic cleft. It should be noted that some of the compounds were inactive despite the presence of a meta or p-(phenoxy)phenyl group (compounds 7a and 8f).
The percent inhibition shown by compound 7n against both DENV2 and WNV was found to be higher than any of the other selected compounds (Figure 2 ). The apparent IC 50 values of compound 7n ( Figure 3 ) were determined to be 6.82 0.09 and 5.51 0.08 µM against DENV2 and WNV protease, respectively. We also performed kinetics analyses to determine the K m , k cat and V max values in the presence and absence of compound 7n at four different concentrations ( Figure 4 and Table 4 Figure 5A , neither of the inactive compounds is predicted to exploit either of the two lipophiles listed above with the same effectiveness as 7n: compound 8f has poor overlap with both lipophiles, and while compound 7a is predicted to achieve some -stacking with Tyr161, its furan group is not situated anywhere near any lipophiles. In the case of WNV NS2B/NS3pro ( Figure 5B ), reasonablestacking is achieved with Tyr161 in all cases, but the furan group of 7a is again poorly situated, while the phenoxyphenyl group of 8f is not predicted to derive nearly as much a hydrophobic interaction as is achieved by the corresponding phenoxyphenyl group of 7n, whose terminal phenyl group is predicted to wedge favorably between Val72 and the lipophilic portion of neighboring Lys73.
In summary, the studies described herein have demonstrated that the aminobenzamide scaffold can be employed in the synthesis of inhibitors of DENV and WNV NS2B/NS3pro.
Experimental Section
General. 
Biochemistry
DENV2 NS2B/NS3pro expression and purification.
The construction of the pQE30-NS2BH(QR)NS3pro expression plasmid has been described previously. 27 The protease was expressed from E. coli strain Top purified as described. 29 DENV2 NS2B/NS3pro contains the hydrophilic NS2B cofactor peptide (NS2BH) linked to the N-terminal NS3 protease domain via Q-R (P2 and P1 residues at the NS2B-NS3 junction site).
WNV NS2B/NS3pro expression and purification.
The expression and purification of the WNV NS2BH-NS3pro containing the 5 amino acid spacer between the NS2B and NS3pro domains was previously described.
29
In vitro DENV2 and WNV NS2B/NS3pro assays and inhibition studies.
The compounds were dissolved in dimethyl sulfoxide (DMSO) to make 50 mM 
